Lebnan Saad, MD
Pulmonary Disease · Louisville, KYNPI 1689648412
Payments from drug & device makers
Across 721 payments — averaging $145.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$93K
- GSK$1K
- AstraZeneca$1K
- Pfizer$963
- Grifols USA, LLC$882
- Actelion Pharmaceuticals US, Inc.$676
- plus $7K from 45 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$104,754 in reported general payments places this provider in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Louisville
- John McConnellLouisville$3.5M
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Samantha BaahLouisville$226K
- Josephine MeiLouisville$101K
- Tanya WieseLouisville$75K
- Rodrigo CavallazziLouisville$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.